REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Heterocyclic Carbon Compounds Containing A Hetero Ring Having Chalcogen (i.e., O,s,se Or Te) Or Nitrogen As The Only Ring Hetero Atoms Doai > Hetero Ring Is Six-membered And Includes At Least Nitrogen And Oxygen As Ring Hetero Atoms (e.g., Monocyclic 1,2- And 1,3-oxazines, Etc.) > Morpholines (i.e., Fully Hydrogenated 1,4- Oxazines) > Having -c(=x)-, Wherein X Is Chalcogen, Bonded Directly To The Morpholine Ring Having -c(=x)-, Wherein X Is Chalcogen, Bonded Directly To The Morpholine RingHaving -c(=x)-, Wherein X Is Chalcogen, Bonded Directly To The Morpholine Ring patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.01/25/07 - 20070021421 - Measurement of gait dynamics and use of beta-blockers to detect, prognose, prevent and treat amyotrophic lateral sclerosis The present invention, at least in part, provides methods of improved early diagnosis of neurodegenerative disease, e.g., ALS, in a subject via measurement of the gait dynamics of the subject (e.g., via the exemplary ventral plane videography methods disclosed herein). The present invention also provides for administration of a beta-adrenergic ... 01/18/07 - 20070015755 - Novel compounds and compositions as protease inhibitors The present invention relates to novel N-cyanomethyl amides which are cysteine protease inhibitors, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making. ... 01/04/07 - 20070004726 - Pharmaceutical/cosmetic compositions comprising novel ligands that activate rar receptors and are suited for formulation into pharmaceutical compositions useful in human or veterinary medicine, or, alternatively, into cosmetic compositions. ... 01/04/07 - 20070004725 - Novel derivatives of amino acids for treatment of obesity and related disorders Novel amino acid derivatives are provided that are useful for management of disorders such as obesity and immunological diseases. The derivatives are also useful in lowering blood glucose levels in hyperglycemic disorders and for treating related disorders such as body weight gain, elevated free fatty acid, cholesterol and triglyceride levels ... 01/04/07 - 20070004724 - (+)-(2s,3s)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinor for treating anxiety This invention relates to a novel method of treatment employing (+)-(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol hydrochloride or a salt or solvate thereof, in particular its use in the treatment of anxiety disorders or in the treatment of mixed anxiety-depressive disorder. ... 12/21/06 - 20060287317 - Sphingosine kinase inhibitors The invention relates to substituted adamantane compounds, pharmaceutical compositions thereof, processes for their preparation, and methods for inhibiting sphingosine kinase and for treating or preventing hyperproliferative disease, inflammatory disease, or angiogenic disease. ... 12/21/06 - 20060287316 - Method for improving pharmacokinetics of protease inhibitors and protease inhibitor precursors when the compound of formula I comprises an amino group, pharmaceutically acceptable ammonium salts thereof, wherein R1 may be, for example, (HO)2P(O)—, (NaO)2P(O)—, alkyl-CO— or cycloalkyl-CO—, wherein X may be, for example, F, Cl, and Br, and wherein R2 and R3 are as defined herein. ... 12/07/06 - 20060276472 - Pharmaceutical composition intended for the prevention or for the treatment of cerebral oedemas or at least one of the pharmaceutically acceptable salts thereof, for the preparation of a medicament intended for the prevention or for the treatment of cerebral oedemas. ... 11/09/06 - 20060252753 - Aminocycloalkyl cinnamide compounds for arrhythmia and as analgesics and anesthetics Aminocycloalkyl cinnamide compounds are disclosed. The compounds of the present invention may be incorporated in compositions and kits. The present invention also discloses a variety of in vitro and in vivo uses for the compounds and compositions, including the treatment of arrhythmia and the production of local analgesia and anesthesia. ... 10/12/06 - 20060229309 - Novel isophthalates as beta-secretase inhibitors or a stereoisomer thereof; or a pharmaceutically acceptable salt thereof, wherein W, R3, R5 and R6 as defined herein, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein (APP) by β-secretase and, more specifically, inhibit the production of Aβ-peptide. The present disclosure ... 09/14/06 - 20060205727 - Combination therapy for endothelial dysfunction, angina and diabetes The combination of a HMG CoA reductase inhibitor like a statin, such as simvastatin, with a pFox inhibitor such as trimetazidine (“Simetazidine”) is particularly advantageous for treatment of end-stage complications, such as acute coronary syndrome (ACS) and chronic angina, especially in type II diabetics. The combination therapy is also useful ... 09/14/06 - 20060205726 - Ester derivatives and medical use thereof or a pharmaceutically acceptable salt thereof. ... 09/07/06 - 20060199822 - Bis-sulfonamide hydroxyethylamino retroviral protease inhibitors or a pharmaceutically acceptable salt, prodrug or ester thereof, wherein the variables are as defined herein. ... 08/24/06 - 20060189612 - Pharmaceutically active morpholinol Disclosed is the compound (+)-(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol and pharmaceutically acceptable salts and solvates thereof, pharmaceutical compositions comprising them, and processes for their preparation and use; also disclosed is a method of treating depression, attention deficit hyperactivity disorder (ADHD), obesity, migraine, pain, sexual dysfunction, Parkinson's disease, Alzheimer's disease, or addiction to cocaine or ... 08/10/06 - 20060178366 - Compounds for the treatment of inflammatory disorders or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, aggrecanase, ADMP, LpxC, ADAMs, TACE, TNF-α or combinations thereof. ... 08/03/06 - 20060173006 - Compounds for inflammation and immune-related uses or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, wherein X1, X2, X3, Y, Z, L, R1, R2, R3, R18 and n are defined herein. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders. ... 08/03/06 - 20060173005 - Process for preparing nitrooxyderivative of naproxen wherein R is as defined above and Z is hydrogen or a cation selected from: Li+, Na+, K+, Ca++, Mg++, tetralkylammonium, tetralkylphosphonium, with a compound of formula (C), as reported in the description, wherein R1-R12 and m, n, o, p, q, r, s are as defined above and Y is ... 07/27/06 - 20060166990 - Novel aminobenzophenone compounds The invention provides novel compounds according to formula I relates to compounds with the general formula I said compounds being useful, e.g. in the treatment of inflammatory, ophthalmic diseases or cancer. ... 07/27/06 - 20060166989 - 2-naphthamide derivatives The present invention relates to 2-naphthamides, which are useful as an active ingredient of pharmaceutical preparations. The 2-naphthamides of the present invention have IP receptor antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with IP receptor activity. Such diseases include urological diseases or disorder ... 07/20/06 - 20060160805 - Thiotungstate analogues and uses thereof The current invention provides novel thiotungstate derivatives, methods of making novel thiotungstate derivatives, pharmaceutical compositions of novel thiotungstate derivatives, methods of using novel thiotungstate derivatives to treat diseases associated with aberrant vascularization, copper metabolism disorders and obesity and methods of using pharmaceutical compositions of thiotungstate derivatives to treat diseases associated ... 07/13/06 - 20060154927 - Fungicidal mixtures for combating rice pathogens in which X is chlorine or fluorine, in a synergistically effective amount, methods for controlling rice pathogens using mixtures of the compound I with the compounds II, the use of the compound I and the compounds II for preparing such mixtures and compositions comprising these mixtures are described. ... // - 2) an acryloylmorpholide of the formula II, - ... // - 1) the triazolopyrimidine derivative of the formula I, - ... 07/13/06 - 20060154926 - Methods of treating alzheimer's disease using aryl alkanoic acid amides Disclosed are methods for treating Alzheimer's disease, and other diseases, and/or inhibiting beta-secretase enzyme, and/or inhibiting deposition of A beta peptide in a mammal, by use of compounds of formula (1) wherein the variables R1-R8 and X are defined herein. ... 07/06/06 - 20060148799 - Substituted p-phenyl carbamates Novel substituted p-phenyl carbamates, pharmaceutical compositions comprising them and use thereof in the treatment and/or prevention of diseases and disorders related to hormone sensitive lipase. More particularly, the compounds are useful for the treatment and/or prevention of diseases and disorders in which modulation of the activity of hormone sensitive lipase ... 06/15/06 - 20060128705 - Method of treating chronic fatigue syndrome Methods and compositions for treating humans suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or a condition where inhibiting reuptake of norepinephrine is a benefit are disclosed. The compositions comprise a compound having a pharmacological selectivity of serotonin (Ki)/norepinephrine (Ki) of at least about ... 06/15/06 - 20060128704 - Tetrahydro-naphthalene derivatives in which R1 represents hydrogen or C1-6 alkyl, and X represents —N(H)Y1, —N(H)—C1-6 alkylene Y1, biphenyl or C1-6 alkyl substituted by biphenyl, and the group Y1 is an optionally substituted biphenyl. The tetrahydro-naphthalene derivatives of the present invention have excellent activity as VR1 antagonists and are useful for the prophylaxis ... 05/18/06 - 20060106017 - Novel o-acyloxime derivatives, preparation method thereof, and pharmaceutical composition containing the same for prevention and treatment of cardiovascular disease The present invention relates to novel O-acyloxime derivatives, a preparation method thereof and a pharmaceutical composition comprising the same for prevention and treatment of cardiovascular disease. The O-acyloxime derivatives according to the present invention may valuably be used for prevention and treatment of cardiovascular diseases such as hyperlipidemia, coronary arterial ... 04/27/06 - 20060089357 - Novel compounds and compositions as cathepsin inhibitors The present invention relates to novel cathepsin S inhibitors, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making. ... 04/20/06 - 20060084648 - Ethynyl derivatives as factor xa inhibitors Novel compounds of the formula (I), in which R1, R2, R3, X and Y have the meaning indicated in Patent claim 1, are inhibitors ocoagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic diseases and for the treatment of tumours. ... 04/13/06 - 20060079525 - Morpholin-acetamide derivatives for the treatment of inflammatory diseases wherein R1, R2, R3, R4, R5, X, a, b and Z are as defined in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases. ... 04/06/06 - 20060074086 - Phenyl derivatives and methods of use Novel phenyl compounds, pharmaceutical compositions containing these compounds, and methods for their pharmaceutical use are disclosed. In certain embodiments, the compounds are agonists and/or ligands of cannabinoid receptors and may be useful, inter alia, for treating and/or preventing pain, gastrointestinal disorders, genitourinary disorders, inflammation, glaucoma, auto-immune diseases, ischemic conditions, immune-related ... 03/23/06 - 20060063764 - Insect repellents Use of an N-substituted p-menthane carboxamide as an active ingredient in an insect repellent composition, which has little or no odour and which is substantially non-toxic for human, pet and livestock. ... 03/16/06 - 20060058298 - Inhibitors of histone deacetylase The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions. ... 03/16/06 - 20060058297 - Novel compounds useful for modulating abnormal cell proliferation There is described compounds of Formulae I, II, III, IV and V. The compounds of Formulae I, II, III, IV and/or V are useful: in therapeutic methods and compositions for modulating cell proliferation, in diagnostic assays and as research tools. ... 02/23/06 - 20060040938 - Substituted fullerene compositions and their use as antioxidants (ii) u>O groups bonded to the fullerene core, wherein u is an integer from 0 to 12, inclusive ... 02/02/06 - 20060025416 - Substituted aryl acylthioureas and related compounds; inhibitors of viral replication The invention further comprises methods of treating patients suffering from certain infectious diseases by administering to such patients an amount of a compound of Formula I effective to reduce signs or symptoms of the disease or disorder. These infectious diseases include viral infections, particularly HCV infections. The invention is particularly ... 01/26/06 - 20060019955 - Oculoselective drugs and prodrugs wherein each R6 is independently H, straight chain or branched C1-C10 alkyl, or straight chain or branched C1-C10 alkoxyalkyl. Methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of treating patients by administration of the pharmaceutical compositions, are also disclosed. ... 01/26/06 - 20060019954 - Method for reducing the likelihood of the occurrence of cardiac arrhythmias A method is described for reducing the likelihood of the occurrence of a cardiac arrhythmias of the type leading to sudden cardiac death in a mammalian subject. The method comprises administering to the mammalian subject an effective amount of a composition to agonize β3 adrenergic receptors in the mammalian subject. ... 10/20/05 - 20050234058 - Secondary amino-and cycloamino-cycloalkanol derivatives and methods of their use The present invention is directed to secondary amino- and cycloamino-cycloalkanol derivatives, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system ... 10/13/05 - 20050227982 - Antileishmanial dinitroaniline sulfanomides with activity against parasite tubulin Dinitroaniline compounds useful for the treatment of diseases caused by parasitic protozoa in subjects in need of such treatment. The compounds are particularly useful in the treatment of leishmaniasis. The compounds are preferably less cytotoxic to normal cells than oryzalin. Also provided are methods of treating subjects having diseases caused ... 08/18/05 - 20050182057 - Aryl n-cyanoguanidines and methods related thereto including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein R1-5 are as defined herein. The methods of this invention are directed to administering to a warm-blooded animal in need thereof an effective amount of a compound of structure (I), typically in the form of a pharmaceutical composition. ... 08/18/05 - 20050182056 - Modified release formulations of at least one form of tramadol The present invention provides for a modified release pharmaceutical composition comprising at least one form of tramadol selected from the group consisting of tramadol, enantiomers thereof, pharmaceutically acceptable salts thereof and combinations thereof, the composition exhibiting an in vitro dissolution profile (measured using the USP Basket Method at 75 rpm ... 08/04/05 - 20050171103 - Benzamide derivatives useful as histone deacetylase inhibitors The invention concerns a compound of the formula (I) wherein Ring A is heterocyclyl; m is 0-4 and each R1 is a group such as hydroxy, halo, trifluoromethyl and cyano; R2 is, halo and n is 0-2; and each R4 is a group such as hydroxy, halo, trifluoromethyl and cyano; ... 07/07/05 - 20050148588 - Lfa-1 antagonist compounds wherein Cy, X, Y, L and R1-6 are as defined herein. The compounds bind CD11/CD18 adhesion receptors such as Lymphocyte Function-associated Antigen-1 (LFA-1) and are therefore useful for treating disorders mediated by LFA-1 such as inflammation and autoimmune diseases. ... 06/09/05 - 20050124618 - Methods of modulating angiogenesis and cancer cell proliferation Methods for regulating angiogenesis by modulating the activity of 20-HETE are disclosed. Further disclosed are methods of inhibiting cancer and tumor cell growth by exposing the cancer and tumor cells to 20-HETE inhibitors. ... 06/02/05 - 20050119264 - Tetrahydrobenzfluorene derivatives R1 and R2 are independently (1C-4C)alkyl, (2C-4C)alkenyl, hydroxy(2C-4C)alkyl, (1C-3C)alkoxy(2C-4C)alkyl, aryl or aryl(1C-2C)alkyl; or R1 and R2 together with the nitrogen form an aromatic or non-aromatic heterocyclic ring structure, optionally mono- or poly-substituted with (1C-4C)alkyl, (2C-4C)alkenyl, hydroxy(1C-2C)alkyl, (1C-2C)alkoxy(1C-3C)alkyl or aryl. These compounds can be used for estrogen receptor P selective medical ... 06/02/05 - 20050119263 - Treatment of breast cancer Patients with aggressive breast cancer, including patients with estrogen receptor (ER) negative tumors and/or patients who have a disease-free interval from diagnosis to metastatic relapse of less than 36 months, have greater survival times than by treatment with DPPE and doxorubicin than patients receiving doxorubicin alone. Greater survival times are ... ### FreshPatents.com Support |